FdaApplication
NDA 217660
Identifiers
- fda_app_no: NDA217660
Properties
| Property | Value |
|---|---|
| applicant_name | VERTEX PHARMACEUTICALS INC |
| application_type | NDA |
| approval_date | 2023-04-26 |
Revenue by product
TRIKAFTA (COPACKAGED)
| Period | Revenue |
|---|---|
| Q2 2026 | $2.5B* |
| Q1 2026 | $2.4B* |
| Q4 2025 | $2.6B* |
| Q3 2025 | $2.7B* |
| Q2 2025 | $2.6B* |
| Q1 2025 | $2.5B* |
| Q4 2024 | $2.7B* |
| Q3 2024 | $2.6B* |
| Q2 2024 | $2.4B* |
| Q1 2024 | $2.5B* |
| Q4 2023 | $2.3B* |
| Q3 2023 | $2.3B* |
| Q2 2023 | $2.2B* |
| Q1 2023 | $2.1B* |
| Q4 2022 | $2.0B* |
| Q3 2022 | $2.0B* |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| TRIKAFTA (COPACKAGED) | ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR | 100MG, 75MG, 50MG;75MG | GRANULE;ORAL |
| TRIKAFTA (COPACKAGED) | ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR | 80MG, 60MG, 40MG;59.5MG | GRANULE;ORAL |
2 products